IL254148B - Compositions and methods for intravitreal delivery of polynucleotides to retinal cones - Google Patents

Info

Publication number

IL254148B

IL254148B IL254148A IL25414817A IL254148B IL 254148 B IL254148 B IL 254148B IL 254148 A IL254148 A IL 254148A IL 25414817 A IL25414817 A IL 25414817A IL 254148 B IL254148 B IL 254148B

Authority

IL

Israel

Prior art keywords

cone

raav

variant

aav

subject

Prior art date

2015-03-02

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims description 93
• 108091033319 polynucleotide Proteins 0.000 title claims description 22
• 102000040430 polynucleotide Human genes 0.000 title claims description 22
• 239000002157 polynucleotide Substances 0.000 title claims description 22
• 210000001525 retina Anatomy 0.000 title description 74
• 238000002360 preparation method Methods 0.000 title description 9
• 241000702421 Dependoparvovirus Species 0.000 claims description 124
• 108090000623 proteins and genes Proteins 0.000 claims description 111
• 150000001413 amino acids Chemical class 0.000 claims description 101
• 230000014509 gene expression Effects 0.000 claims description 79
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 71
• 210000000964 retinal cone photoreceptor cell Anatomy 0.000 claims description 45
• 108090000565 Capsid Proteins Proteins 0.000 claims description 42
• 102100023321 Ceruloplasmin Human genes 0.000 claims description 42
• 208000035475 disorder Diseases 0.000 claims description 33
• 230000004438 eyesight Effects 0.000 claims description 27
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 26
• 241000288906 Primates Species 0.000 claims description 23
• 102000004169 proteins and genes Human genes 0.000 claims description 21
• 208000002780 macular degeneration Diseases 0.000 claims description 19
• 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 17
• 230000001225 therapeutic effect Effects 0.000 claims description 16
• 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 15
• 201000006754 cone-rod dystrophy Diseases 0.000 claims description 15
• 201000007790 vitelliform macular dystrophy Diseases 0.000 claims description 14
• 206010025412 Macular dystrophy congenital Diseases 0.000 claims description 13
• 101000598988 Mus musculus Medium-wave-sensitive opsin 1 Proteins 0.000 claims description 13
• 241000282414 Homo sapiens Species 0.000 claims description 12
• 101001137074 Homo sapiens Long-wave-sensitive opsin 1 Proteins 0.000 claims description 11
• 102100035576 Long-wave-sensitive opsin 1 Human genes 0.000 claims description 11
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 11
• 208000034461 Progressive cone dystrophy Diseases 0.000 claims description 10
• 206010043189 Telangiectasia Diseases 0.000 claims description 10
• 201000008615 cone dystrophy Diseases 0.000 claims description 10
• 208000009056 telangiectasis Diseases 0.000 claims description 10
• 208000017442 Retinal disease Diseases 0.000 claims description 9
• 230000006872 improvement Effects 0.000 claims description 9
• 201000001408 X-linked juvenile retinoschisis 1 Diseases 0.000 claims description 8
• 208000017441 X-linked retinoschisis Diseases 0.000 claims description 8
• 229920001184 polypeptide Polymers 0.000 claims description 8
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
• 201000007714 retinoschisis Diseases 0.000 claims description 8
• 208000036693 Color-vision disease Diseases 0.000 claims description 7
• 208000004644 retinal vein occlusion Diseases 0.000 claims description 7
• 239000003623 enhancer Substances 0.000 claims description 6
• 208000027073 Stargardt disease Diseases 0.000 claims description 5
• 239000002773 nucleotide Substances 0.000 claims description 5
• 125000003729 nucleotide group Chemical group 0.000 claims description 5
• 230000001105 regulatory effect Effects 0.000 claims description 5
• 208000036443 AIPL1-related retinopathy Diseases 0.000 claims description 4
• 208000022758 Sorsby fundus dystrophy Diseases 0.000 claims description 4
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
• 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 3
• 208000032253 retinal ischemia Diseases 0.000 claims description 2
• 238000011144 upstream manufacturing Methods 0.000 claims description 2
• 125000003275 alpha amino acid group Chemical group 0.000 claims 4
• 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 claims 2
• 201000006902 exudative vitreoretinopathy Diseases 0.000 claims 2
• 208000021089 Coats disease Diseases 0.000 claims 1
• 208000008069 Geographic Atrophy Diseases 0.000 claims 1
• 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims 1
• 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims 1
• 208000008709 Retinal Telangiectasis Diseases 0.000 claims 1
• 108700009124 Transcription Initiation Site Proteins 0.000 claims 1
• 210000004027 cell Anatomy 0.000 description 200
• 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 109
• 239000013598 vector Substances 0.000 description 90
• 235000001014 amino acid Nutrition 0.000 description 81
• 210000001508 eye Anatomy 0.000 description 58
• 239000000203 mixture Substances 0.000 description 47
• 238000012360 testing method Methods 0.000 description 47
• 230000003612 virological effect Effects 0.000 description 47
• 108700019146 Transgenes Proteins 0.000 description 46
• 101710197658 Capsid protein VP1 Proteins 0.000 description 45
• 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 44
• 201000010099 disease Diseases 0.000 description 38
• 239000007924 injection Substances 0.000 description 36
• 238000002347 injection Methods 0.000 description 36
• 230000006870 function Effects 0.000 description 34
• 241000700605 Viruses Species 0.000 description 32
• 239000000047 product Substances 0.000 description 30
• 230000002207 retinal effect Effects 0.000 description 30
• 239000002253 acid Substances 0.000 description 29
• 210000000234 capsid Anatomy 0.000 description 26
• 208000024891 symptom Diseases 0.000 description 25
• 241001465754 Metazoa Species 0.000 description 23
• 230000000694 effects Effects 0.000 description 22
• 150000003839 salts Chemical class 0.000 description 21
• 210000001519 tissue Anatomy 0.000 description 21
• 238000012014 optical coherence tomography Methods 0.000 description 20
• 208000006992 Color Vision Defects Diseases 0.000 description 19
• 241000699694 Gerbillinae Species 0.000 description 19
• 206010025421 Macule Diseases 0.000 description 19
• 238000003780 insertion Methods 0.000 description 19
• 230000037431 insertion Effects 0.000 description 19
• 235000018102 proteins Nutrition 0.000 description 19
• 150000002500 ions Chemical class 0.000 description 18
• 201000007254 color blindness Diseases 0.000 description 17
• 150000001875 compounds Chemical class 0.000 description 17
• 239000002245 particle Substances 0.000 description 17
• 210000002845 virion Anatomy 0.000 description 17
• 230000035772 mutation Effects 0.000 description 16
• 201000004569 Blindness Diseases 0.000 description 15
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 15
• 230000002829 reductive effect Effects 0.000 description 15
• 230000004393 visual impairment Effects 0.000 description 15
• 230000004456 color vision Effects 0.000 description 14
• 206010012601 diabetes mellitus Diseases 0.000 description 14
• 239000008194 pharmaceutical composition Substances 0.000 description 14
• 108091008695 photoreceptors Proteins 0.000 description 14
• 108020003589 5' Untranslated Regions Proteins 0.000 description 13
• 241000699666 Mus <mouse, genus> Species 0.000 description 13
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
• 238000003384 imaging method Methods 0.000 description 13
• 239000002953 phosphate buffered saline Substances 0.000 description 13
• 238000001727 in vivo Methods 0.000 description 12
• 150000007523 nucleic acids Chemical group 0.000 description 12
• 230000004304 visual acuity Effects 0.000 description 12
• 108020004707 nucleic acids Proteins 0.000 description 11
• 102000039446 nucleic acids Human genes 0.000 description 11
• -1 peptid e Proteins 0.000 description 11
• 108091026890 Coding region Proteins 0.000 description 10
• 241000700159 Rattus Species 0.000 description 10
• 101150057833 THEG gene Proteins 0.000 description 10
• 238000011282 treatment Methods 0.000 description 10
• 239000013603 viral vector Substances 0.000 description 10
• 230000000007 visual effect Effects 0.000 description 10
• 208000010412 Glaucoma Diseases 0.000 description 9
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 9
• 241000124008 Mammalia Species 0.000 description 9
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
• 238000001802 infusion Methods 0.000 description 9
• 102000010175 Opsin Human genes 0.000 description 8
• 108050001704 Opsin Proteins 0.000 description 8
• 201000000761 achromatopsia Diseases 0.000 description 8
• 239000000872 buffer Substances 0.000 description 8
• 230000006378 damage Effects 0.000 description 8
• 230000003247 decreasing effect Effects 0.000 description 8
• 229920002866 paraformaldehyde Polymers 0.000 description 8
• 210000003583 retinal pigment epithelium Anatomy 0.000 description 8
• 239000011780 sodium chloride Substances 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 239000000725 suspension Substances 0.000 description 8
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
• 206010003694 Atrophy Diseases 0.000 description 7
• 241000282552 Chlorocebus aethiops Species 0.000 description 7
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 7
• 108060001084 Luciferase Proteins 0.000 description 7
• 239000005089 Luciferase Substances 0.000 description 7
• 241000699670 Mus sp. Species 0.000 description 7
• 108091028043 Nucleic acid sequence Proteins 0.000 description 7
• 240000007594 Oryza sativa Species 0.000 description 7
• 229930040373 Paraformaldehyde Natural products 0.000 description 7
• 230000037444 atrophy Effects 0.000 description 7
• 238000000338 in vitro Methods 0.000 description 7
• 208000015181 infectious disease Diseases 0.000 description 7
• 229960003299 ketamine Drugs 0.000 description 7
• 239000013612 plasmid Substances 0.000 description 7
• 241000283690 Bos taurus Species 0.000 description 6
• 108020004414 DNA Proteins 0.000 description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 6
• 101001104102 Homo sapiens X-linked retinitis pigmentosa GTPase regulator Proteins 0.000 description 6
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
• 201000003533 Leber congenital amaurosis Diseases 0.000 description 6
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
• 241000283973 Oryctolagus cuniculus Species 0.000 description 6
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
• 102100040092 X-linked retinitis pigmentosa GTPase regulator Human genes 0.000 description 6
• 230000003044 adaptive effect Effects 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 238000004519 manufacturing process Methods 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 230000008447 perception Effects 0.000 description 6
• 230000002093 peripheral effect Effects 0.000 description 6
• 230000000750 progressive effect Effects 0.000 description 6
• 239000013608 rAAV vector Substances 0.000 description 6
• 241000894007 species Species 0.000 description 6
• 238000010186 staining Methods 0.000 description 6
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 6
• 241000649045 Adeno-associated virus 10 Species 0.000 description 5
• 108091006146 Channels Proteins 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 208000035719 Maculopathy Diseases 0.000 description 5
• 208000001140 Night Blindness Diseases 0.000 description 5
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 5
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 5
• 125000000539 amino acid group Chemical group 0.000 description 5
• 201000010018 blue color blindness Diseases 0.000 description 5
• 150000001768 cations Chemical class 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 230000007547 defect Effects 0.000 description 5
• 238000012217 deletion Methods 0.000 description 5
• 230000037430 deletion Effects 0.000 description 5
• 238000003745 diagnosis Methods 0.000 description 5
• 239000003814 drug Substances 0.000 description 5
• 238000002474 experimental method Methods 0.000 description 5
• 239000012634 fragment Substances 0.000 description 5
• 239000003550 marker Substances 0.000 description 5
• 239000000049 pigment Substances 0.000 description 5
• 239000000523 sample Substances 0.000 description 5
• 230000003595 spectral effect Effects 0.000 description 5
• 201000003632 spinocerebellar ataxia type 7 Diseases 0.000 description 5
• BGRJTUBHPOOWDU-UHFFFAOYSA-N sulpiride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-UHFFFAOYSA-N 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• 230000000699 topical effect Effects 0.000 description 5
• 239000013607 AAV vector Substances 0.000 description 4
• 241001655883 Adeno-associated virus - 1 Species 0.000 description 4
• 241000202702 Adeno-associated virus - 3 Species 0.000 description 4
• 241000580270 Adeno-associated virus - 4 Species 0.000 description 4
• 241001634120 Adeno-associated virus - 5 Species 0.000 description 4
• 241000972680 Adeno-associated virus - 6 Species 0.000 description 4
• 241001164823 Adeno-associated virus - 7 Species 0.000 description 4
• 241001164825 Adeno-associated virus - 8 Species 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 201000009188 Bardet-Biedl syndrome 1 Diseases 0.000 description 4
• 102100021295 Bardet-Biedl syndrome 1 protein Human genes 0.000 description 4
• 241000283707 Capra Species 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• 241000238631 Hexapoda Species 0.000 description 4
• 101000894722 Homo sapiens Bardet-Biedl syndrome 1 protein Proteins 0.000 description 4
• 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 4
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
• 241000699684 Meriones unguiculatus Species 0.000 description 4
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
• 206010030113 Oedema Diseases 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
• 150000001412 amines Chemical class 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 210000004204 blood vessel Anatomy 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 230000004064 dysfunction Effects 0.000 description 4
• 239000013604 expression vector Substances 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 238000001415 gene therapy Methods 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• 244000005700 microbiome Species 0.000 description 4
• 230000003287 optical effect Effects 0.000 description 4
• 238000004806 packaging method and process Methods 0.000 description 4
• 239000000790 retinal pigment Substances 0.000 description 4
• 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 4
• 238000003757 reverse transcription PCR Methods 0.000 description 4
• 239000004576 sand Substances 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 239000004055 small Interfering RNA Substances 0.000 description 4
• 208000011580 syndromic disease Diseases 0.000 description 4
• 238000010361 transduction Methods 0.000 description 4
• 230000026683 transduction Effects 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
• 208000009278 Blue cone monochromatism Diseases 0.000 description 3
• 241000282465 Canis Species 0.000 description 3
• 102100029362 Cone-rod homeobox protein Human genes 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 229920002307 Dextran Polymers 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 241000283073 Equus caballus Species 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 101000899806 Homo sapiens Retinal guanylyl cyclase 1 Proteins 0.000 description 3
• 101001104110 Homo sapiens X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Proteins 0.000 description 3
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
• 206010056715 Laurence-Moon-Bardet-Biedl syndrome Diseases 0.000 description 3
• 241000713666 Lentivirus Species 0.000 description 3
• 208000022873 Ocular disease Diseases 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 206010034960 Photophobia Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 206010038848 Retinal detachment Diseases 0.000 description 3
• 102100022663 Retinal guanylyl cyclase 1 Human genes 0.000 description 3
• 206010038910 Retinitis Diseases 0.000 description 3
• 102100040756 Rhodopsin Human genes 0.000 description 3
• 241001593290 Rhodopsis Species 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• 241000024109 Spiris Species 0.000 description 3
• 208000027418 Wounds and injury Diseases 0.000 description 3
• 102100040089 X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Human genes 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 239000005557 antagonist Substances 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• 230000002146 bilateral effect Effects 0.000 description 3
• 230000027455 binding Effects 0.000 description 3
• 201000007728 blue cone monochromacy Diseases 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 230000003915 cell function Effects 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 230000007812 deficiency Effects 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 230000007717 exclusion Effects 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 238000013534 fluorescein angiography Methods 0.000 description 3
• 210000000873 fovea centralis Anatomy 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 238000007429 general method Methods 0.000 description 3
• 238000003364 immunohistochemistry Methods 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 208000014674 injury Diseases 0.000 description 3
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 3
• 238000002372 labelling Methods 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 238000000386 microscopy Methods 0.000 description 3
• 230000004297 night vision Effects 0.000 description 3
• 206010029864 nystagmus Diseases 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 229940002612 prodrug Drugs 0.000 description 3
• 239000000651 prodrug Substances 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 201000000757 red-green color blindness Diseases 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 230000004434 saccadic eye movement Effects 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 229960001600 xylazine Drugs 0.000 description 3
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
• CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 2
• NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 2
• DPZHKLJPVMYFCU-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)acetonitrile Chemical compound BrC1=CC=C(CC#N)N=C1 DPZHKLJPVMYFCU-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• 241000024188 Andala Species 0.000 description 2
• 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 2
• 108010032953 Ataxin-7 Proteins 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 201000001321 Bardet-Biedl syndrome Diseases 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 206010065941 Central obesity Diseases 0.000 description 2
• 102100035673 Centrosomal protein of 290 kDa Human genes 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 102100039484 Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha' Human genes 0.000 description 2
• 102100029140 Cyclic nucleotide-gated cation channel beta-3 Human genes 0.000 description 2
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
• 206010011906 Death Diseases 0.000 description 2
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
• 241000283074 Equus asinus Species 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 241000282324 Felis Species 0.000 description 2
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
• 241000287828 Gallus gallus Species 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 102100039214 Guanine nucleotide-binding protein G(t) subunit alpha-2 Human genes 0.000 description 2
• 239000012981 Hank's balanced salt solution Substances 0.000 description 2
• 208000028782 Hereditary disease Diseases 0.000 description 2
• 101000609790 Homo sapiens Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha' Proteins 0.000 description 2
• 101000919370 Homo sapiens Cone-rod homeobox protein Proteins 0.000 description 2
• 101000771083 Homo sapiens Cyclic nucleotide-gated cation channel beta-3 Proteins 0.000 description 2
• 101000888142 Homo sapiens Guanine nucleotide-binding protein G(t) subunit alpha-2 Proteins 0.000 description 2
• 101001044118 Homo sapiens Inosine-5'-monophosphate dehydrogenase 1 Proteins 0.000 description 2
• 101000598987 Homo sapiens Medium-wave-sensitive opsin 1 Proteins 0.000 description 2
• 101000996052 Homo sapiens Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 Proteins 0.000 description 2
• 101000597428 Homo sapiens Nucleoredoxin-like protein 1 Proteins 0.000 description 2
• 101000610652 Homo sapiens Peripherin-2 Proteins 0.000 description 2
• 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 2
• 101000726148 Homo sapiens Protein crumbs homolog 1 Proteins 0.000 description 2
• 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 2
• 101000742938 Homo sapiens Retinol dehydrogenase 12 Proteins 0.000 description 2
• 101001120990 Homo sapiens Short-wave-sensitive opsin 1 Proteins 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 102100021602 Inosine-5'-monophosphate dehydrogenase 1 Human genes 0.000 description 2
• 108091092195 Intron Proteins 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• 102100033356 Lecithin retinol acyltransferase Human genes 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
• 102100037812 Medium-wave-sensitive opsin 1 Human genes 0.000 description 2
• 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 2
• 102100034451 Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 Human genes 0.000 description 2
• 102100035399 Nucleoredoxin-like protein 1 Human genes 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• 241001504519 Papio ursinus Species 0.000 description 2
• 102100040375 Peripherin-2 Human genes 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 102100040120 Prominin-1 Human genes 0.000 description 2
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
• 102100027331 Protein crumbs homolog 1 Human genes 0.000 description 2
• 208000002367 Retinal Perforations Diseases 0.000 description 2
• 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 2
• 102100038054 Retinol dehydrogenase 12 Human genes 0.000 description 2
• 108090000820 Rhodopsin Proteins 0.000 description 2
• 101150054830 S100A6 gene Proteins 0.000 description 2
• 241000555745 Sciuridae Species 0.000 description 2
• 206010039729 Scotoma Diseases 0.000 description 2
• 101710106192 Short-wave-sensitive opsin 1 Proteins 0.000 description 2
• 102100026557 Short-wave-sensitive opsin 1 Human genes 0.000 description 2
• 108091027967 Small hairpin RNA Proteins 0.000 description 2
• 108020004459 Small interfering RNA Proteins 0.000 description 2
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• 241000282887 Suidae Species 0.000 description 2
• 241000282898 Sus scrofa Species 0.000 description 2
• 241000949477 Toona ciliata Species 0.000 description 2
• 206010047513 Vision blurred Diseases 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 230000000692 anti-sense effect Effects 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 238000005415 bioluminescence Methods 0.000 description 2
• 230000029918 bioluminescence Effects 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 210000004155 blood-retinal barrier Anatomy 0.000 description 2
• 230000004378 blood-retinal barrier Effects 0.000 description 2
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
• 102000014823 calbindin Human genes 0.000 description 2
• 108060001061 calbindin Proteins 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 238000002659 cell therapy Methods 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 230000003292 diminished effect Effects 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 208000011325 dry age related macular degeneration Diseases 0.000 description 2
• 230000004424 eye movement Effects 0.000 description 2
• 102000005396 glutamine synthetase Human genes 0.000 description 2
• 108020002326 glutamine synthetase Proteins 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 229940093915 gynecological organic acid Drugs 0.000 description 2
• 238000007654 immersion Methods 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000010354 integration Effects 0.000 description 2
• 239000007927 intramuscular injection Substances 0.000 description 2
• 238000010255 intramuscular injection Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 239000000644 isotonic solution Substances 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 238000004020 luminiscence type Methods 0.000 description 2
• 229920002521 macromolecule Polymers 0.000 description 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
• 239000011976 maleic acid Substances 0.000 description 2
• 239000001630 malic acid Substances 0.000 description 2
• 235000011090 malic acid Nutrition 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 229940098779 methanesulfonic acid Drugs 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 235000006408 oxalic acid Nutrition 0.000 description 2
• 230000005043 peripheral vision Effects 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229920005862 polyol Polymers 0.000 description 2
• 150000003077 polyols Chemical class 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• 210000001747 pupil Anatomy 0.000 description 2
• 230000004439 pupillary reactions Effects 0.000 description 2
• 201000000763 red color blindness Diseases 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 230000004264 retinal detachment Effects 0.000 description 2
• 210000003786 sclera Anatomy 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 108010080511 serum sodium transport inhibitor Proteins 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
• PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 241000701447 unidentified baculovirus Species 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• 208000029257 vision disease Diseases 0.000 description 2
• 238000011179 visual inspection Methods 0.000 description 2
• WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
• OVBICQMTCPFEBS-SATRDZAXSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound CC(O)=O.CC(O)=O.C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 OVBICQMTCPFEBS-SATRDZAXSA-N 0.000 description 1
• PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
• TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
• CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• GHIVDTCFLFLOBV-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-acetyloxybenzoate Chemical compound CCN(CC)CCOC(=O)C1=CC=CC=C1OC(C)=O GHIVDTCFLFLOBV-UHFFFAOYSA-N 0.000 description 1
• KLDZYURQCUYZBL-UHFFFAOYSA-N 2-[3-[(2-hydroxyphenyl)methylideneamino]propyliminomethyl]phenol Chemical compound OC1=CC=CC=C1C=NCCCN=CC1=CC=CC=C1O KLDZYURQCUYZBL-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
• WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
• 108020005345 3' Untranslated Regions Proteins 0.000 description 1
• NJXWZWXCHBNOOG-UHFFFAOYSA-N 3,3-diphenylpropyl(1-phenylethyl)azanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1C(C)[NH2+]CCC(C=1C=CC=CC=1)C1=CC=CC=C1 NJXWZWXCHBNOOG-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
• WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
• QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
• ZVNPWFOVUDMGRP-UHFFFAOYSA-N 4-methylaminophenol sulfate Chemical compound OS(O)(=O)=O.CNC1=CC=C(O)C=C1.CNC1=CC=C(O)C=C1 ZVNPWFOVUDMGRP-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 230000035502 ADME Effects 0.000 description 1
• 241000649046 Adeno-associated virus 11 Species 0.000 description 1
• 241000649047 Adeno-associated virus 12 Species 0.000 description 1
• 239000012103 Alexa Fluor 488 Substances 0.000 description 1
• 241000232400 Andrena <genus> Species 0.000 description 1
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
• 101100437118 Arabidopsis thaliana AUG1 gene Proteins 0.000 description 1
• 101100437119 Arabidopsis thaliana AUG2 gene Proteins 0.000 description 1
• 235000017060 Arachis glabrata Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 235000010777 Arachis hypogaea Nutrition 0.000 description 1
• 235000018262 Arachis monticola Nutrition 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 102100024081 Aryl-hydrocarbon-interacting protein-like 1 Human genes 0.000 description 1
• BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 102000007368 Ataxin-7 Human genes 0.000 description 1
• 206010003671 Atrioventricular Block Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 208000000412 Avitaminosis Diseases 0.000 description 1
• 101150077415 BEST1 gene Proteins 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
• 102100022794 Bestrophin-1 Human genes 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
• 238000011740 C57BL/6 mouse Methods 0.000 description 1
• 102100022002 CD59 glycoprotein Human genes 0.000 description 1
• 102100035344 Cadherin-related family member 1 Human genes 0.000 description 1
• 101100165202 Caenorhabditis elegans bbs-1 gene Proteins 0.000 description 1
• 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 108090000397 Caspase 3 Proteins 0.000 description 1
• 102100029855 Caspase-3 Human genes 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 241000282692 Catarrhini Species 0.000 description 1
• 101710198317 Centrosomal protein of 290 kDa Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 239000004380 Cholic acid Substances 0.000 description 1
• 206010008795 Chromatopsia Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 238000006873 Coates reaction Methods 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 108010003730 Cone Opsins Proteins 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 102000018361 Contactin Human genes 0.000 description 1
• 108060003955 Contactin Proteins 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 102100029142 Cyclic nucleotide-gated cation channel alpha-3 Human genes 0.000 description 1
• 102100029141 Cyclic nucleotide-gated cation channel beta-1 Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
• AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 208000006558 Dental Calculus Diseases 0.000 description 1
• 206010012335 Dependence Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
• 102100024361 Disintegrin and metalloproteinase domain-containing protein 9 Human genes 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 206010070917 Eccentric fixation Diseases 0.000 description 1
• 102100032053 Elongation of very long chain fatty acids protein 4 Human genes 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 241001492222 Epicoccum Species 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 206010015958 Eye pain Diseases 0.000 description 1
• 206010015995 Eyelid ptosis Diseases 0.000 description 1
• 239000001263 FEMA 3042 Substances 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
• 229930091371 Fructose Natural products 0.000 description 1
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
• 239000005715 Fructose Substances 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 101150066002 GFP gene Proteins 0.000 description 1
• 241000132519 Galactites Species 0.000 description 1
• IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 206010064571 Gene mutation Diseases 0.000 description 1
• 241000282575 Gorilla Species 0.000 description 1
• 102100033969 Guanylyl cyclase-activating protein 1 Human genes 0.000 description 1
• 241000696272 Gull adenovirus Species 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 208000010271 Heart Block Diseases 0.000 description 1
• 108091060210 Heavy strand Proteins 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 241000282418 Hominidae Species 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 101000594506 Homo sapiens Acyl-coenzyme A diphosphatase NUDT19 Proteins 0.000 description 1
• 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
• 101000833576 Homo sapiens Aryl-hydrocarbon-interacting protein-like 1 Proteins 0.000 description 1
• 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 description 1
• 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
• 101000737767 Homo sapiens Cadherin-related family member 1 Proteins 0.000 description 1
• 101000771071 Homo sapiens Cyclic nucleotide-gated cation channel alpha-3 Proteins 0.000 description 1
• 101000771075 Homo sapiens Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 description 1
• 101000832769 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 9 Proteins 0.000 description 1
• 101000921354 Homo sapiens Elongation of very long chain fatty acids protein 4 Proteins 0.000 description 1
• 101001068480 Homo sapiens Guanylyl cyclase-activating protein 1 Proteins 0.000 description 1
• 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
• 101001011412 Homo sapiens IQ calmodulin-binding motif-containing protein 1 Proteins 0.000 description 1
• 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 1
• 101001047038 Homo sapiens Inward rectifier potassium channel 13 Proteins 0.000 description 1
• 101001017786 Homo sapiens Lecithin retinol acyltransferase Proteins 0.000 description 1
• 101000583150 Homo sapiens Membrane-associated phosphatidylinositol transfer protein 3 Proteins 0.000 description 1
• 101000781361 Homo sapiens Protein XRP2 Proteins 0.000 description 1
• 101001074528 Homo sapiens Regulating synaptic membrane exocytosis protein 1 Proteins 0.000 description 1
• 101001132674 Homo sapiens Retina and anterior neural fold homeobox protein 2 Proteins 0.000 description 1
• 101000710852 Homo sapiens Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma Proteins 0.000 description 1
• 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 1
• 101000611338 Homo sapiens Rhodopsin Proteins 0.000 description 1
• 101000609947 Homo sapiens Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha Proteins 0.000 description 1
• 101000609949 Homo sapiens Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta Proteins 0.000 description 1
• 101000652369 Homo sapiens Spermatogenesis-associated protein 7 Proteins 0.000 description 1
• 101000772173 Homo sapiens Tubby-related protein 1 Proteins 0.000 description 1
• 101000805941 Homo sapiens Usherin Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 241000282596 Hylobatidae Species 0.000 description 1
• 208000031226 Hyperlipidaemia Diseases 0.000 description 1
• 206010020675 Hypermetropia Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 102100029842 IQ calmodulin-binding motif-containing protein 1 Human genes 0.000 description 1
• 102100036881 Inositol-3-phosphate synthase 1 Human genes 0.000 description 1
• 102100022843 Inward rectifier potassium channel 13 Human genes 0.000 description 1
• 241000764238 Isis Species 0.000 description 1
• 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 1
• 201000002287 Keratoconus Diseases 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 201000009709 Leber congenital amaurosis 11 Diseases 0.000 description 1
• 201000010480 Leber congenital amaurosis 13 Diseases 0.000 description 1
• 201000008886 Leber congenital amaurosis 14 Diseases 0.000 description 1
• 201000002502 Leber congenital amaurosis 8 Diseases 0.000 description 1
• 208000010415 Low Vision Diseases 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 208000001344 Macular Edema Diseases 0.000 description 1
• 206010025415 Macular oedema Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 206010025476 Malabsorption Diseases 0.000 description 1
• 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102100030351 Membrane-associated phosphatidylinositol transfer protein 3 Human genes 0.000 description 1
• 208000024556 Mendelian disease Diseases 0.000 description 1
• 241000087624 Monoclona Species 0.000 description 1
• 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
• 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
• 101100343498 Mus musculus Lipn gene Proteins 0.000 description 1
• 208000006550 Mydriasis Diseases 0.000 description 1
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 238000011887 Necropsy Methods 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
• 101150046816 PRPH2 gene Proteins 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 241000282576 Pan paniscus Species 0.000 description 1
• 241000282520 Papio Species 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
• YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
• 206010034962 Photopsia Diseases 0.000 description 1
• 241000288935 Platyrrhini Species 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 241000282405 Pongo abelii Species 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
• 108010001267 Protein Subunits Proteins 0.000 description 1
• 102000002067 Protein Subunits Human genes 0.000 description 1
• 102100033154 Protein XRP2 Human genes 0.000 description 1
• 208000036575 RDH12-related recessive retinopathy Diseases 0.000 description 1
• 230000006819 RNA synthesis Effects 0.000 description 1
• 230000004570 RNA-binding Effects 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 238000011529 RT qPCR Methods 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 208000005587 Refsum Disease Diseases 0.000 description 1
• 102100036240 Regulating synaptic membrane exocytosis protein 1 Human genes 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 102100033908 Retina and anterior neural fold homeobox protein 2 Human genes 0.000 description 1
• 102100033844 Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma Human genes 0.000 description 1
• 201000007737 Retinal degeneration Diseases 0.000 description 1
• 206010057430 Retinal injury Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 1
• 101710137010 Retinol-binding protein 3 Proteins 0.000 description 1
• 102100038247 Retinol-binding protein 3 Human genes 0.000 description 1
• 102100039177 Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha Human genes 0.000 description 1
• 102100039174 Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta Human genes 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 101000733871 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L4-A Proteins 0.000 description 1
• 101000733875 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L4-B Proteins 0.000 description 1
• 241000435809 Sarea Species 0.000 description 1
• 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 208000020221 Short stature Diseases 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 102100030257 Spermatogenesis-associated protein 7 Human genes 0.000 description 1
• 101000942604 Sphingomonas wittichii (strain DC-6 / KACC 16600) Chloroacetanilide N-alkylformylase, oxygenase component Proteins 0.000 description 1
• 241000569510 Spino Species 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• JXASPPWQHFOWPL-UHFFFAOYSA-N Tamarixin Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 JXASPPWQHFOWPL-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 102100028644 Tenascin-R Human genes 0.000 description 1
• 102100035115 Testin Human genes 0.000 description 1
• 101710070533 Testin Proteins 0.000 description 1
• 241000278713 Theora Species 0.000 description 1
• 241000011102 Thera Species 0.000 description 1
• 101150079992 Timp3 gene Proteins 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 208000031861 Tritanopia Diseases 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
• 102100029293 Tubby-related protein 1 Human genes 0.000 description 1
• 108090000704 Tubulin Proteins 0.000 description 1
• 102000004243 Tubulin Human genes 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 206010045178 Tunnel vision Diseases 0.000 description 1
• 102100022356 Tyrosine-protein kinase Mer Human genes 0.000 description 1
• 241000566576 Tyto Species 0.000 description 1
• 208000014769 Usher Syndromes Diseases 0.000 description 1
• 102100037930 Usherin Human genes 0.000 description 1
• XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
• 108020005202 Viral DNA Proteins 0.000 description 1
• 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
• 206010047627 Vitamin deficiencies Diseases 0.000 description 1
• 208000034699 Vitreous floaters Diseases 0.000 description 1
• 208000034698 Vitreous haemorrhage Diseases 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 208000026724 Waardenburg syndrome Diseases 0.000 description 1
• 239000005862 Whey Substances 0.000 description 1
• 102000007544 Whey Proteins Human genes 0.000 description 1
• 108010046377 Whey Proteins Proteins 0.000 description 1
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
• DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• 208000004622 abetalipoproteinemia Diseases 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 208000030597 adult Refsum disease Diseases 0.000 description 1
• VFRROHXSMXFLSN-SLPGGIOYSA-N aldehydo-D-glucose 6-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O VFRROHXSMXFLSN-SLPGGIOYSA-N 0.000 description 1
• 150000001323 aldoses Chemical class 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 150000001447 alkali salts Chemical class 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• 150000001371 alpha-amino acids Chemical class 0.000 description 1
• 235000008206 alpha-amino acids Nutrition 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• HESIBZMZTMHXQS-UHFFFAOYSA-M alumanyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[AlH2] HESIBZMZTMHXQS-UHFFFAOYSA-M 0.000 description 1
• 229960004909 aminosalicylic acid Drugs 0.000 description 1
• 230000003444 anaesthetic effect Effects 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 238000002583 angiography Methods 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 238000000149 argon plasma sintering Methods 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 230000003190 augmentative effect Effects 0.000 description 1
• BCTILSWHJRTUIE-UHFFFAOYSA-N azanium;4-[4-[bis[4-(dimethylamino)phenyl]-hydroxymethyl]-3-methyl-5-oxo-4h-pyrazol-1-yl]benzenesulfonate Chemical compound [NH4+].C1=CC(N(C)C)=CC=C1C(O)(C=1C=CC(=CC=1)N(C)C)C1C(=O)N(C=2C=CC(=CC=2)S([O-])(=O)=O)N=C1C BCTILSWHJRTUIE-UHFFFAOYSA-N 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 239000003855 balanced salt solution Substances 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
• 229940064804 betadine Drugs 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 238000011685 brown norway rat Methods 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 229960004203 carnitine Drugs 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
• 239000002458 cell surface marker Substances 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 210000003161 choroid Anatomy 0.000 description 1
• 210000004081 cilia Anatomy 0.000 description 1
• HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 230000008045 co-localization Effects 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 208000031513 cyst Diseases 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 201000011190 diabetic macular edema Diseases 0.000 description 1
• 239000012973 diazabicyclooctane Substances 0.000 description 1
• SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical compound [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 208000029436 dilated pupil Diseases 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000013024 dilution buffer Substances 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 238000012137 double-staining Methods 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 238000002571 electroretinography Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 238000002813 epsilometer test Methods 0.000 description 1
• DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 210000000887 face Anatomy 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 238000000799 fluorescence microscopy Methods 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 230000005021 gait Effects 0.000 description 1
• LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
• 108700032141 ganirelix Proteins 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000009368 gene silencing by RNA Effects 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 230000001295 genetical effect Effects 0.000 description 1
• 230000004313 glare Effects 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229940097043 glucuronic acid Drugs 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 125000005639 glycero group Chemical group 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 125000001475 halogen functional group Chemical group 0.000 description 1
• 230000010370 hearing loss Effects 0.000 description 1
• 231100000888 hearing loss Toxicity 0.000 description 1
• 208000016354 hearing loss disease Diseases 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 201000006318 hyperopia Diseases 0.000 description 1
• 230000004305 hyperopia Effects 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 238000010191 image analysis Methods 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229960004717 insulin aspart Drugs 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 230000004410 intraocular pressure Effects 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 101150085091 lat-2 gene Proteins 0.000 description 1
• 208000025014 late infantile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
• 108010084957 lecithin-retinol acyltransferase Proteins 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 208000018769 loss of vision Diseases 0.000 description 1
• 231100000864 loss of vision Toxicity 0.000 description 1
• 201000010230 macular retinal edema Diseases 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• SWHAQEYMVUEVNF-UHFFFAOYSA-N magnesium potassium Chemical compound [Mg].[K] SWHAQEYMVUEVNF-UHFFFAOYSA-N 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000036244 malformation Effects 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 210000004779 membrane envelope Anatomy 0.000 description 1
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 108091070501 miRNA Proteins 0.000 description 1
• 239000002679 microRNA Substances 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
• 208000005340 mucopolysaccharidosis III Diseases 0.000 description 1
• 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 description 1
• 208000001491 myopia Diseases 0.000 description 1
• 230000004379 myopia Effects 0.000 description 1
• 210000004126 nerve fiber Anatomy 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 210000005157 neural retina Anatomy 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 206010030875 ophthalmoplegia Diseases 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 238000012536 packaging technology Methods 0.000 description 1
• WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
• 238000004091 panning Methods 0.000 description 1
• 208000008016 pathologic nystagmus Diseases 0.000 description 1
• 231100000915 pathological change Toxicity 0.000 description 1
• 230000036285 pathological change Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 235000020232 peanut Nutrition 0.000 description 1
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 210000003668 pericyte Anatomy 0.000 description 1
• 239000012466 permeate Substances 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 230000000649 photocoagulation Effects 0.000 description 1
• 210000000608 photoreceptor cell Anatomy 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 239000002798 polar solvent Substances 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 208000003580 polydactyly Diseases 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000001124 posttranscriptional effect Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 238000003825 pressing Methods 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 229960003981 proparacaine Drugs 0.000 description 1
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
• 238000001814 protein method Methods 0.000 description 1
• 201000003004 ptosis Diseases 0.000 description 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 239000013643 reference control Substances 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000004258 retinal degeneration Effects 0.000 description 1
• 230000004287 retinal location Effects 0.000 description 1
• 230000004250 retinal swelling Effects 0.000 description 1
• 230000004268 retinal thickening Effects 0.000 description 1
• 210000001210 retinal vessel Anatomy 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• JZWFDVDETGFGFC-UHFFFAOYSA-N salacetamide Chemical group CC(=O)NC(=O)C1=CC=CC=C1O JZWFDVDETGFGFC-UHFFFAOYSA-N 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 230000003584 silencer Effects 0.000 description 1
• 230000004599 slow eye movement Effects 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 229940063673 spermidine Drugs 0.000 description 1
• 229940063675 spermine Drugs 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 229930193551 sterin Natural products 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 229910021653 sulphate ion Inorganic materials 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229920002258 tannic acid Polymers 0.000 description 1
• 235000015523 tannic acid Nutrition 0.000 description 1
• 229940033123 tannic acid Drugs 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 108010020387 tenascin R Proteins 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 230000002110 toxicologic effect Effects 0.000 description 1
• 231100000759 toxicological effect Toxicity 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 239000012096 transfection reagent Substances 0.000 description 1
• 102000027257 transmembrane receptors Human genes 0.000 description 1
• 108091008578 transmembrane receptors Proteins 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
• 238000009966 trimming Methods 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 229960004791 tropicamide Drugs 0.000 description 1
• 230000010415 tropism Effects 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 238000009777 vacuum freeze-drying Methods 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 210000000264 venule Anatomy 0.000 description 1
• 238000012795 verification Methods 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• 230000004382 visual function Effects 0.000 description 1
• 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 238000010626 work up procedure Methods 0.000 description 1
• 239000000811 xylitol Substances 0.000 description 1
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
• 235000010447 xylitol Nutrition 0.000 description 1
• 229960002675 xylitol Drugs 0.000 description 1
• 239000001052 yellow pigment Substances 0.000 description 1